

Targeted treatments for early HER2-negative breast cancer have different mechanisms of action¹



PARP inhibitors

cause cell death in tumor cells with a BRCA mutation by inhibiting DNA repair¹



CDK4/6 inhibitors

affect the cell cycle and decrease cell proliferation^{1,2}



PD-1/PD-L1 inhibitors

modulate the immune system and increase immune response¹

Treatment informed by predictive biomarkers may lead to improved patient outcomes and may help avoid some side effects of non-targeted treatments as well as their attendant costs.³



Test early for BRCA mutations